Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acotec Scientific Holdings (HKSE:06669) Total Current Assets Explanation
In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.
Acotec Scientific Holdings's Liquidation Value for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acotec Scientific Holdings Total Current Assets Related Terms
Acotec Scientific Holdings Total Current Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acotec Scientific Holdings Total Current Assets Chart
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.
What does a Total Current Assets of HK$1,476.9 Mil mean?
Acotec Scientific Holdings (HKSE:06669) has a Total Current Assets of HK$1,476.9 Mil as of Dec. 2025. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Acotec Scientific Holdings and its competitors.
Is Acotec Scientific Holdings' Total Current Assets too high?
Acotec Scientific Holdings' current Total Current Assets is HK$1,476.9 Mil. Overall, Acotec Scientific Holdings has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Acotec Scientific Holdings' Total Current Assets compare to ABT and SYK?
Acotec Scientific Holdings' Total Current Assets of HK$1,476.9 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Medical Devices & Instruments company?
A good Total Current Assets depends on the Medical Devices & Instruments industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Acotec Scientific Holdings and its competitors. Acotec Scientific Holdings's current Total Current Assets is HK$1,476.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acotec Scientific Holdings stock overvalued right now?
Based on GuruFocus' analysis, Acotec Scientific Holdings (HKSE:06669) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$14.84, compared to a current price of HK$6.24 — trading 58% below its estimated fair value. The current Total Current Assets is HK$1,476.9 Mil. Acotec Scientific Holdings' overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Acotec Scientific Holdings (HKSE:06669), the current Total Current Assets is HK$1,476.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acotec Scientific Holdings (HKSE:06669) Overvalued in 2026?
Based on GuruFocus' analysis, Acotec Scientific Holdings stock appears to be undervalued.
The current stock price of HK$6.24 is trading 58% below its estimated GF Value™ of HK$14.84.
GuruFocus considers Acotec Scientific Holdings to be Significantly Undervalued.
Key valuation signals for HKSE:06669:
Total Current Assets: HK$1,476.9 Mil
GF Value™: HK$14.84 vs. price of HK$6.24 (58% below fair value)
No single metric tells the full story. See the HKSE:06669 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acotec Scientific Holdings Ltd is a medical technology company, focusing on the research and development, and application of technology platforms in the field of vascular interventional treatment. Its product portfolio comprises Semi-compliant PTCA balloon (YAN), Coronary CTO Recanalization Balloon (RT-Zero), Coronary CTO Antegrade Micro-Catheter (Vericor-14), Coronary High-Pressure Balloon (YIYAN), Coronary CTO Retrograde Micro-Catheter (Vericor-RS), Cardiac Valve Balloon Dilation Catheter (RunFlow), etc., and also has various other products in its development pipeline. Geographically, the company generates a majority of its revenue from Mainland China, and the rest from other regions. The firm generates the majority of its revenue from sales to Domestic distributors.
76GF Score
Get the complete analysis for HKSE:06669
Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06669 has been successfully added to your 
